General
Preferred name
ZOLEDRONIC ACID
Synonyms
Zoledronic acid hydrate ()
Zometa ()
CGP42446A ()
ZOL 446 ()
Zoledronate ()
CGP 42446 ()
ZOLEDRONIC ACID ANHYDROUS ()
Zoledronate monohydrate ()
Zoledronic Acid (Zoledronate) ()
Zoledronic acid (monohydrate) ()
Zoledronic acidZometaZoledronateCPG 42446(1-Hydroxy-2-imidazol-1-ylethylidene)diphosphonic acidPhosphonic acid,[1-hydroxy-2-(1H-imidazol-1-yl)ethylidene]bis- ()
Zoledronic acid (ZOL 446) ()
ZA, Zoledronate, CGP-4244, GP42446A, ZOL 446, Zometa, Zomera, Aclasta, Reclast ()
CGP 42446 monohydrate ()
CGP42446A monohydrate ()
ZOL 446 monohydrate ()
CGP-42446A ()
CGP-42446 ()
Zoledronic acid medac ()
Aclasta ()
Zoledronic acid teva ()
Zoledronic acid monohydrate ()
Zoledronic acid teva generics ()
Zoledronic acid hospira ()
Zoledronic acid actavis ()
Zoledronic acid mylan ()
Zoledronate hydrate ()
Acido zoledronico ()
Zoledronic acid teva pharma ()
Reclast ()
AK-156 ()
Zerlinda ()
Zoladrona acid mylan ()
Zoledronic ()
NSC-721517 ()
Zoledronic acid accord ()
Acide zoledronique ()
Anhydrous zoledronic acid ()
Zoledronic acid disodium salt tetrahydrate ()
CGP 42446A ()
Zoledronate disodium tetrahydrate ()
Zoledronate disodium hydrate ()
ZOLEDRONATE DISODIUM ()
CGP-42446B ()
CGP 42446B ()
Zoledronic acid trisodium salt hydrate ()
ZOLEDRONATE TRISODIUM ()
Zoledronic Acid (hydrate) ()
Zoledronate D,L-Lysine Monohydrate ()
P&D ID
PD004076
CAS
118072-93-8
165800-06-6
165800-08-8
Tags
available
drug
drug candidate
Approved by
EMA
FDA
First approval
2001
Drug indication
Hypercalcaemia
Adenocarcinoma
Renal cell carcinoma
Drug Status
approved
investigational
Max Phase
4.0
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
PRICE 29
DESCRIPTION Zoledronic acid monohydrate (CGP 42446) is a synthetic imidazole bisphosphonate analog with anti-bone-resorption activity.
DESCRIPTION Marketed formulations may contain zoledronic acid monohydrate (PubChem CID 121586). (GtoPdb)
PRICE 29
DESCRIPTION Zoledronic acid (zoledronate) is a bisphosphonate bone resorption inhibitor, an inhibitor of farnesyl diphosphate (FPP) synthase which results in downstream inhibition of osteoclast activity and reduced bone resorption and turnover. It has been used to treat postmenopausal osteoporosis, Paget's disease, hypercalcemia, and along with cancer chemotherapy to treat bone damage caused by cancer that has spread to the bones. (BOC Sciences Bioactive Compounds)
DESCRIPTION Zoledronic acid is a third generation, nitrogen containing bisphosphonate that inhibits osteoclast function and prevents bone resorption. It is used to treat malignancy associated hypercalcemia, multiple myeloma, and bone metastasis from solid tumors. (Enamine Bioactive Compounds)
DESCRIPTION Potent and selective allosteric activator of AMPK (Tocris Bioactive Compound Library)
DESCRIPTION Zoledronic acid induces apoptosis in osteoclasts by inhibiting enzymes of the mevalonate pathway and preventing the isoprenylation of small GTP-binding proteins such as Ras and Rho. (BOC Sciences Bioactive Compounds)
DESCRIPTION Zoledronic Acid (ZOL 446) is a bisphosphonate. Zoledronic Acid (ZOL 446) is used to prevent skeletal fractures in patients with cancers such as multiple myeloma and prostate cancer. It can also be used to treat hypercalcemia of malignancy and can be helpful for treating pain from bone metastases. An annual dose of Zoledronate may also prevent recurring fractures in patients with a previous hip fracture. Zoledronic Acid (ZOL 446) is a single 5 mg infusion for the treatment of Paget's disease of bone. In 2007, the FDA also approved Reclast for the treatment of postmenopausal osteoporosis. (TargetMol Bioactive Compound Library)
Cell lines
16
Organisms
6
Compound Sets
37
AdooQ Bioactive Compound Library
Cayman Chemical Bioactives
ChEMBL Approved Drugs
Concise Guide to Pharmacology 2017/18
Concise Guide to Pharmacology 2019/20
Concise Guide to Pharmacology 2021/22
Concise Guide to Pharmacology 2023/24
Concise Guide to Pharmacology 2025/26
CZ-OPENSCREEN Bioactive Library
Drug Repurposing Hub
DrugBank Approved Drugs
DrugCentral
DrugCentral Approved Drugs
DrugMAP
DrugMAP Approved Drugs
DrugMatrix
Enamine Bioactive Compounds
Enamine BioReference Compounds
Guide to Pharmacology
LSP-MoA library (Laboratory of Systems Pharmacology)
Mcule NIBR MoA Box Subset
MedChem Express Bioactive Compound Library
NCATS Inxight Approved Drugs
NIH Approved Oncology Drugs
Novartis Chemogenetic Library (NIBR MoA Box)
NPC Screening Collection
Prestwick Chemical Library
Probe Miner (suitable probes)
ReFrame library
Selleckchem Bioactive Compound Library
TargetMol Bioactive Compound Library
The Spectrum Collection
Tocris Bioactive Compound Library
ZINC Tool Compounds
External IDs
462
Properties
(calculated by RDKit )
Molecular Weight
272.0
Hydrogen Bond Acceptors
5
Hydrogen Bond Donors
5
Rotatable Bonds
4
Ring Count
1
Aromatic Ring Count
1
cLogP
-1.12
TPSA
153.11
Fraction CSP3
0.4
Chiral centers
0.0
Largest ring
5.0
QED
0.43
Structural alerts
0
No structural alerts detected
Custom attributes
(extracted from source data)
Pathway
Apoptosis
Autophagy
Cell Cycle/Checkpoint
Anti-infection
Primary Target
Other Synthases/Synthetases
MOA
Inhibitor
Angiogenesis Inhibitors
bone resorption inhibitor
Member status
member
Target
FDPS, GGPS1
Bacterial
Apoptosis related,Autophagy,Ras,Rho
Rho
Indication
Paget's disease
Therapeutic Class
Bone Density Conservation Agents
Source data